Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Cyxone

Less than 1K followers
All
Research
Press releases
3rd party
ShowingAll content types

Press release2024-11-26 17:00

Interim CFO lämnar Cyxone

Cyxone
Press release2024-11-11 15:31

BioStock: Cyxone handelsstoppades och erhöll betalningskrav

Cyxone
Regulatory press release2024-11-08 14:06

Cyxone erhåller betalningskrav om knappt 5 miljoner kronor

Cyxone

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release2024-08-29 08:50

Cyxone: Delårsrapport 2024-04-01 till 2024-06-30

Cyxone
Regulatory press release2024-08-26 14:19

Cyxone AB announces last day of trading in BTA

Cyxone
Regulatory press release2024-08-26 14:19

Cyxone AB meddelar sista dag för handel med BTA

Cyxone
Regulatory press release2024-08-16 08:59

Cyxone AB publicerar utfall i genomförd företrädesemission

Cyxone
Regulatory press release2024-08-16 08:59

Cyxone AB publishes outcome of rights issue

Cyxone
Press release2024-08-13 09:55

BioStock: Cyxones vd om värdering av läkemedelsprojekt

Cyxone
Press release2024-08-08 10:34

BioStock: Emission ska realisera nya kliniska framsteg för Cyxone

Cyxone
Press release2024-08-01 09:37

BioStock: Cyxones vd: "Väsentligt lägre risk i projektutvecklingen"

Cyxone
Regulatory press release2024-08-01 08:45

Teckningstiden i Cyxones företrädesemission inleds idag

Cyxone
Regulatory press release2024-08-01 08:45

The subscription period in Cyxone's rights issue starts today

Cyxone
Regulatory press release2024-07-31 08:45

Cyxone AB publishes investment memorandum

Cyxone
Regulatory press release2024-07-31 08:45

Cyxone AB publicerar investeringsmemorandum

Cyxone
Press release2024-07-23 13:07

BioStock: Cyxone uppdaterar utvecklingsplanen

Cyxone
Regulatory press release2024-07-23 08:30

Cyxone: Styrelsen beslutar om företrädesemission om högst cirka 23 MSEK för att finansiera fortsatt utveckling av rabeximod och T20K

Cyxone
Regulatory press release2024-07-23 08:30

Cyxone: The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K

Cyxone
Press release2024-07-15 08:42

Cyxone provides an update on its research and development program

Cyxone
Press release2024-07-15 08:42

Cyxone uppdaterar sitt forsknings- och utvecklingsprogram

Cyxone